STERIS plc — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
STERIS plc entered into a new $1,600,000,000 revolving credit agreement dated November 4, 2026, with JPMorgan Chase Bank and J.P. Morgan SE as administrative agents, replacing the prior October 7, 2024 facility. The new agreement serves to finance the Xodus Medical acquisition (Target), refinance Target's existing debt, and fund other transaction costs. Four borrowers (STERIS plc, STERIS Limited, STERIS Corporation, STERIS Irish FinCo) and multiple guarantors are party to this facility, which matures five years from closing.
Why this rating
Routine refinancing of revolving credit facility at same size ($1.6B); modest extension of maturity (5 years) is standard. Relative to $24.2B market cap, financing size is ~6.6% of company value—material but not transformative for a mature industrial firm.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.